The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model

Molecular Cancer Therapeutics

Volumn 8, Issue 4, 2009, Pages 930-939

  VanderPorten, Erica C ^a   Taverna, Pietro ^a   Hogan, Jennifer N ^a   Ballinger, Marcus D ^a   Flanagan, W Michael ^a   Fucini, Raymond V ^a  

^a Sunesis Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AURORA KINASE INHIBITOR; CARBOPLATIN; DAUNORUBICIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; PACLITAXEL; PROTEIN P53; SNS 314; TAXOTERE R; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; AURORA KINASE; CARBANILAMIDE DERIVATIVE; ENZYME INHIBITOR; PROTEIN SERINE THREONINE KINASE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOMA CELL; CELL CULTURE; CELL DEATH; CELL LINE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINESIS; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MICROTUBULE; MITOSIS SPINDLE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; TREATMENT DURATION; XENOGRAFT; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; COLON TUMOR; DISEASE MODEL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICROTUBULES; MITOTIC SPINDLE APPARATUS; PHENYLUREA COMPOUNDS; PROTEIN-SERINE-THREONINE KINASES; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66449133562     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0754     Document Type: Article

References (40)

1. Andrews PD. Aurora kinases: shining lights on the therapeutic horizon? Oncogene 2005;24:5005-5015
2. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10. (Pubitemid 46246762)
3. Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008;1786:60-72.
4. Kollareddy M, DzubakP , Zheleva D, Hajduch M. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:27-33.
5. Katayama H, Sasai K, Kloc M, Brinkley BR, Sen S. Aurora kinase-A regulates kinetochore/chromatin associated microtubule assembly in human cells. Cell Cycle 2008;7:2691-2704
6. Sen S, Katayama H, Sasai K. Functional significance of Aurora kinase A in centrosome amplification and genomic instability. Adv Exp Med Biol 2008;617:99-108.
7. Ditchfield C, Johnson VL, Tighe A, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003;161:267-280 (Pubitemid 36529846)
8. Hauf S, Cole RW, LaTerra S, et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003;161:281-294 (Pubitemid 36529847)
9. Sasai K, Katayama H, Stenoien DL, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004;59:249-263 (Pubitemid 40012993)
10. Bischoff JR, Anderson L, Zhu Y, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-3065 (Pubitemid 28254378)
11. Chieffi P, Cozzolino L, Kisslinger A, et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 2006;66:326-333 (Pubitemid 43191232)
12. Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S. Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 2004;25:1631-1639
13. Hu W, Kavanagh JJ, Deaver M, et al. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res 2005;15:49-57. (Pubitemid 40470532)
14. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004;10:2065-2071 (Pubitemid 38375568)
15. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22:451-464 (Pubitemid 36791899)
16. Landen CN, Jr., Lin YG, Immaneni A, et al. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 2007;13:4098-4104
17. Royce ME, Xia W, Sahin AA, et al. STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 2004;100:12-19 (Pubitemid 37553534)
18. Tanaka E, Hashimoto Y, Ito T, et al. The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005;11:1827-1834 (Pubitemid 40471846)
19. Tchatchou S, Wirtenberger M, Hemminki K, et al. Aurora kinases A and B and familial breast cancer risk. Cancer Lett 2007;247:266-272 (Pubitemid 46240614)
20. Vischioni B, Oudejans JJ, VosW, Rodriguez JA, Giaccone G. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 2006;5:2905-2913 (Pubitemid 44849018)
21. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: new targets for cancer therapy. Clin Cancer Res 2006;12:6869-6875 (Pubitemid 44974478)
22. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Jr., Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1639-1648
23. Girdler F, Gascoigne KE, Eyers PA, et al. Validating Aurora B as an anticancer drug target. J Cell Sci 2006;119:3664-3675 (Pubitemid 44501870)
24. Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 2006;66:4996-5002. (Pubitemid 43844918)
25. Oslob JD, Romanowski MJ, Allen DA, et al. Discovery of a potent and selective aurora kinase inhibitor. Bioorg Med Chem Lett 2008;18:4880-4884
26. Robert F, Hurwitz H, Verschraegen CF, et al. Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients. J Clin Oncol 26:2008 (May 20 suppl; abstr 14642).
27. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL. Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell 2001;12:1315-1328 (Pubitemid 33044413)
28. Gizatullin F, Yao Y, Kung V, Harding MW, Loda M, Shapiro GI. The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 2006;66:7668-7677 (Pubitemid 44289225)
29. Carpinelli P, Ceruti R, Giorgini ML, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-3168
30. Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 2007;6:1851-1857 (Pubitemid 46954062)
31. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004;10:7994-8004. (Pubitemid 39587541)
32. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
33. Pasquier E, Kavallaris M. Microtubules: a dynamic target in cancer therapy. IUBMB Life 2008;60:165-170
34. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-117
35. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004;23:2825-2837 (Pubitemid 38638845)
36. Hoover RR, Haregewoin A, Harding MW. The Aurora kinase inhibitor MK-0457 (VX-680) demonstrates anticancer activity alone or in combination with docetaxel. Eur J Can Supplements (ECCO 14 Meeting Abstract) 5:2007;6.
37. TaoW, South VJ, Zhang Y, et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005;8:49-59. (Pubitemid 40991814)
38. Yang J, Ikezoe T, Nishioka C, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood 2007;110:2034-2040 (Pubitemid 47443920)
39. Sun L, Li D, Dong X, et al. Small-molecule inhibition of Aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells. Biochem Pharmacol 2008;75:1027-1034
40. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-267 (Pubitemid 38667616)